Exhibit 107
CALCULATION OF FILING FEE TABLES
Form S-8
Immunovant, Inc.
Table 1: Newly Registered Securities
| Security Type | Security Class Title |
Fee Calculation Rule |
Amount to be Registered(1) |
Proposed Maximum Offering Price Per Share |
Proposed Maximum Aggregate Offering Price |
Fee Rate |
Amount of Registration Fee(4) | |||||||
| Equity | Common Stock, $0.0001 par value per share | Other(2) | 5,213,194(3) | $15.44 | $80,491,715.36 | 0.00011020 | $8,870.19 | |||||||
| Total Offering Amounts | $80,491,715.36 | $8,870.19 | ||||||||||||
| Total Fee Offsets | ||||||||||||||
| Net Fee Due | $8,870.19 | |||||||||||||
| (1) | Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of common stock (“Common Stock”) of Immunovant, Inc. (the “Registrant”) that become issuable under the Registrant’s 2019 Equity Incentive Plan (the “2019 Plan”) by reason of any stock dividend, stock split, recapitalization or other similar transaction effected that results in an increase to the number of outstanding shares of the Registrant’s Common Stock, as applicable. |
| (2) | Estimated in accordance with Rule 457(h) and Rule 457(c) solely for the purpose of calculating the registration fee on the basis of the average of the high and low prices of the Common Stock as reported on the Nasdaq Global Select Market on April 3, 2023. |
| (3) | Represents an automatic annual increase equal to 4% of the of the total number of shares of Common Stock outstanding on March 31, 2023 to the aggregate number of shares of Common Stock reserved for issuance under the 2019 Plan, pursuant to the terms of the 2019 Plan. |
| (4) | The Registrant does not have any fee offsets. |